Go Pro
→ How to get a stake in Anthropic — before the IPO (From Weiss Ratings) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AlloVir, Inc. stock logo
ALVR
AlloVir
$3.24
-0.2%		$3.85
$7.96
▼
$24.15
$16.34M0.6315,685 shs29,135 shs
BioCardia, Inc. stock logo
BCDA
BioCardia
$1.05
$1.00
$0.75
▼
$1.80
$15.90M0.55367,903 shs140,886 shs
Dyadic International Inc. stock logo
DYAI
Dyadic International
$0.41
+3.7%		$0.78
$0.34
▼
$1.60
$16.02M0.96219,018 shs251,315 shs
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
$0.51
-3.7%		$0.57
$0.47
▼
$1.85
$4.02M2.0524,910 shs24,094 shs
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AlloVir, Inc. stock logo
ALVR
AlloVir
-0.15%+1.25%-21.93%-26.36%-26.36%
BioCardia, Inc. stock logo
BCDA
BioCardia
0.00%-16.00%-0.94%-3.67%-25.53%
Dyadic International Inc. stock logo
DYAI
Dyadic International
+3.72%+3.06%-38.92%-44.01%-61.58%
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
-3.69%+2.28%-7.24%-23.71%-67.22%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AlloVir, Inc. stock logo
ALVR
AlloVir
$3.24
-0.2%		$3.85
$7.96
▼
$24.15
$16.34M0.6315,685 shs29,135 shs
BioCardia, Inc. stock logo
BCDA
BioCardia
$1.05
$1.00
$0.75
▼
$1.80
$15.90M0.55367,903 shs140,886 shs
Dyadic International Inc. stock logo
DYAI
Dyadic International
$0.41
+3.7%		$0.78
$0.34
▼
$1.60
$16.02M0.96219,018 shs251,315 shs
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
$0.51
-3.7%		$0.57
$0.47
▼
$1.85
$4.02M2.0524,910 shs24,094 shs
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AlloVir, Inc. stock logo
ALVR
AlloVir
-0.15%+1.25%-21.93%-26.36%-26.36%
BioCardia, Inc. stock logo
BCDA
BioCardia
0.00%-16.00%-0.94%-3.67%-25.53%
Dyadic International Inc. stock logo
DYAI
Dyadic International
+3.72%+3.06%-38.92%-44.01%-61.58%
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
-3.69%+2.28%-7.24%-23.71%-67.22%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AlloVir, Inc. stock logo
ALVR
AlloVir
0.00
N/AN/AN/A
BioCardia, Inc. stock logo
BCDA
BioCardia
2.00
Hold$25.002,280.95% Upside
Dyadic International Inc. stock logo
DYAI
Dyadic International
2.00
Hold$3.00623.07% Upside
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest MBIO, ALVR, BCDA, and DYAI Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/24/2026
BioCardia, Inc. stock logo
BCDA
BioCardia
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
8/12/2026
Dyadic International Inc. stock logo
DYAI
Dyadic International
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
8/11/2026
BioCardia, Inc. stock logo
BCDA
BioCardia
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong Sell ➝ Hold
7/17/2026
BioCardia, Inc. stock logo
BCDA
BioCardia
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/17/2026
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/13/2026
BioCardia, Inc. stock logo
BCDA
BioCardia
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold ➝ Strong Sell
6/24/2026
Dyadic International Inc. stock logo
DYAI
Dyadic International
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
(Data available from 9/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AlloVir, Inc. stock logo
ALVR
AlloVir
N/AN/AN/AN/A$29.35 per shareN/A
BioCardia, Inc. stock logo
BCDA
BioCardia
N/AN/AN/AN/A$0.08 per shareN/A
Dyadic International Inc. stock logo
DYAI
Dyadic International
$3.09M5.38N/AN/A$0.03 per share13.83
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
N/AN/AN/AN/A$1.31 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AlloVir, Inc. stock logo
ALVR
AlloVir
-$190.42M-$20.23N/AN/AN/AN/A-71.03%-61.27%N/A
BioCardia, Inc. stock logo
BCDA
BioCardia
-$8.23M-$0.64N/AN/AN/AN/A-569.36%-183.15%11/11/2026 (Estimated)
Dyadic International Inc. stock logo
DYAI
Dyadic International
-$7.36M-$0.23N/AN/AN/A-201.43%-2,920.31%-84.77%11/11/2026 (Estimated)
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
-$1.92M-$0.45N/AN/AN/AN/A-34.23%-17.55%11/18/2026 (Estimated)

Latest MBIO, ALVR, BCDA, and DYAI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2026Q2 2026
BioCardia, Inc. stock logo
BCDA
BioCardia
-$0.18-$0.13+$0.05-$0.13N/AN/A
8/12/2026Q2 2026
Dyadic International Inc. stock logo
DYAI
Dyadic International
-$0.0350-$0.06-$0.0250-$0.06$1.03 million$0.96 million
8/5/2026Q2 2026
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
-$140.00-$0.16+$139.84-$0.16N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
AlloVir, Inc. stock logo
ALVR
AlloVir
N/AN/AN/AN/AN/A
BioCardia, Inc. stock logo
BCDA
BioCardia
N/AN/AN/AN/AN/A
Dyadic International Inc. stock logo
DYAI
Dyadic International
N/AN/AN/AN/AN/A
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AlloVir, Inc. stock logo
ALVR
AlloVir
N/A
86.78
86.78
BioCardia, Inc. stock logo
BCDA
BioCardia
N/A
2.09
2.09
Dyadic International Inc. stock logo
DYAI
Dyadic International
4.08
1.65
1.65
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
N/A
1.97
1.97

Institutional Ownership

CompanyInstitutional Ownership
AlloVir, Inc. stock logo
ALVR
AlloVir
66.05%
BioCardia, Inc. stock logo
BCDA
BioCardia
20.57%
Dyadic International Inc. stock logo
DYAI
Dyadic International
27.95%
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
9.95%

Insider Ownership

CompanyInsider Ownership
AlloVir, Inc. stock logo
ALVR
AlloVir
32.07%
BioCardia, Inc. stock logo
BCDA
BioCardia
17.40%
Dyadic International Inc. stock logo
DYAI
Dyadic International
20.90%
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
4.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
AlloVir, Inc. stock logo
ALVR
AlloVir
1105.04 million3.43 millionNo Data
BioCardia, Inc. stock logo
BCDA
BioCardia
2115.14 million12.51 millionOptionable
Dyadic International Inc. stock logo
DYAI
Dyadic International
540.06 million31.69 millionOptionable
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
47.58 million7.27 millionNot Optionable

Recent News About These Companies

MindBio Completes Manufacture and Delivery of First Prototype Edge AI Intoxication and Fatigue Detection Kiosks
June 9, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/09/3308694/0/en/mindbio-completes-manufacture-and-delivery-of-first-prototype-edge-ai-intoxication-and-fatigue-detection-kiosks.html
MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Harnesses Key AI, Voice Analysis to Offer Impairment Solution
May 14, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/14/3294935/0/en/mindbio-therapeutics-corp-cse-mbio-otcqb-mbqif-harnesses-key-ai-voice-analysis-to-offer-impairment-solution.html
IBN Announces Latest Episode of The TechMediaWire Podcast featuring Justin Hanka, CEO of MindBio Therapeutics Corp.
May 12, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/12/3292867/0/en/ibn-announces-latest-episode-of-the-techmediawire-podcast-featuring-justin-hanka-ceo-of-mindbio-therapeutics-corp.html
MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Leveraging AI, Voice Analysis to Develop Intoxication Detection
May 12, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/12/3292850/0/en/mindbio-therapeutics-corp-cse-mbio-otcqb-mbqif-leveraging-ai-voice-analysis-to-develop-intoxication-detection.html
MindBio Announces Closing of Private Placement
April 1, 2026  |  thenewswire.comT
MindBio Announces Private Placement to Raise up to $650,000
February 18, 2026  |  thenewswire.comT
Mustang Bio Inc.
July 25, 2025  |  barrons.comhttps://www.barrons.com/market-data/stocks/mbio/company-people?search_keywords=MBIO&search_statement_type=suggested
Talisker Receives Assay Results from 1105 Level Lateral Development at the Mustang Mine
July 24, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/07/24/3120900/0/en/Talisker-Receives-Assay-Results-from-1105-Level-Lateral-Development-at-the-Mustang-Mine.html
MBIO Soars on Orphan Drug Nod for Investigational Brain Cancer Therapy - Nasdaq
July 10, 2025  |  nasdaq.comhttps://www.nasdaq.com/articles/mbio-soars-orphan-drug-nod-investigational-brain-cancer-therapy
Mustang Bio Stock Jumps 180% After FDA Grants Orphan Drug Status to Brain Cancer Drug
July 10, 2025  |  msn.comhttps://www.msn.com/en-gb/health/medical/mustang-bio-stock-jumps-180-after-fda-grants-orphan-drug-status-to-brain-cancer-drug/ar-AA1Icdp5
Biotech Stock Mustang Bio, Inc. (Nasdaq: MBIO) Soars on Orphan Drug Designation by U.S. FDA
July 9, 2025  |  investorideas.comI
Mustang Bio Inc News (MBIO) - Investing.com
July 9, 2025  |  investing.comhttps://www.investing.com/equities/mustang-bio-news
MBIO Soars on Orphan Drug Nod for Investigational Brain Cancer Therapy
July 8, 2025  |  zacks.comhttps://www.zacks.com/stock/news/2567479/mbio-soars-on-orphan-drug-nod-for-investigational-brain-cancer-therapy?cid=cs-stocknewsapi-ft-analyst_blog|company_news_medical_sector-2567479
Dow Dips 1%; Mustang Bio Shares Spike Higher
July 7, 2025  |  benzinga.comhttps://www.benzinga.com/markets/market-summary/25/07/46279608/dow-dips-1-mustang-bio-shares-spike-higher?utm_source=snapi
This BlackRock stock just spiked over 300%
July 7, 2025  |  finbold.comF
Mustang Bio stock soars after FDA grants orphan drug designation
July 7, 2025  |  investing.comhttps://www.investing.com/news/stock-market-news/mustang-bio-stock-soars-after-fda-grants-orphan-drug-designation-93CH-4124757
Mustang Bio rises after FDA orphan drug status for MB-101
July 7, 2025  |  msn.comhttps://www.msn.com/en-us/money/general/mustang-bio-rises-after-fda-orphan-drug-status-for-mb-101/ar-AA1I7BNs
Mustang Bio Shares Surge After FDA Grants Orphan Drug Status
July 7, 2025  |  msn.comhttps://www.msn.com/en-us/money/companies/mustang-bio-shares-surge-after-fda-grants-orphan-drug-status/ar-AA1I7xz6
Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-101 (IL13Ra2-targeted CAR T-cells) to Treat Astrocytomas and Glioblastoma
July 7, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/07/07/3111023/0/en/mustang-bio-granted-orphan-drug-designation-by-u-s-fda-for-mb-101-il13ra2-targeted-car-t-cells-to-treat-astrocytomas-and-glioblastoma.html
Mustang Bio, Inc. (MBIO) - Yahoo Finance
July 2, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/quote/MBIO/news/

New MarketBeat Followers Over Time

Media Sentiment Over Time

AlloVir stock logo

AlloVir NASDAQ:ALVR

$3.24 -0.01 (-0.15%)
As of 09/22/2026

AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.

BioCardia stock logo

BioCardia NASDAQ:BCDA

$1.05 0.00 (0.00%)
Closing price 09/23/2026 04:00 PM Eastern
Extended Trading
$1.06 +0.00 (+0.48%)
As of 06:06 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.

Dyadic International stock logo

Dyadic International NASDAQ:DYAI

$0.41 +0.01 (+3.73%)
Closing price 09/23/2026 04:00 PM Eastern
Extended Trading
$0.42 +0.00 (+0.27%)
As of 09/23/2026 06:27 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial to demonstrate the safety in humans of a protein produced using the C1 platform. It has also developed the Dapibus thermophilic, a filamentous fungal-based microbial protein production platform to enable the development and large-scale manufacture of cost-effective proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, including food, nutrition, and wellness. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa's Rubic One Health; Joint Development Agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.

Mustang Bio stock logo

Mustang Bio NASDAQ:MBIO

$0.51 -0.02 (-3.69%)
As of 09/23/2026 03:59 PM Eastern

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-117 and MB-217, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-101 CAR T cell program for glioblastoma; MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas